# Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct07162883/  
OnCo record `nct07162883` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of QL2107 and pembrolizumab in lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT07162883 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 122 participants, started 2025-09-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: QL2107; Keytruda®. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: AUCtau,sd of QL2107 and Keytruda; AUCtau,ss of QL2107 and Keytruda. Lung eligibility wording from the registry: "* Disease status: Participants with completely resected, histologically- or cytologically-confirmed (Stage II or IIIA) NSCLC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07162883
- Phase: 3
- Setting: A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison With Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects With Resected Non-Small Cell Lung Cancer
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 122

## Sources

- ClinicalTrials.gov NCT07162883: https://clinicaltrials.gov/study/NCT07162883

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [QL2107](https://onco.cc/drugs/ql2107/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07162883.json